Trials / Completed
CompletedNCT00339144
Study of Dasatinib (BMS-354825) in Patients With Solid Tumors
A Phase I Study of BMS-354825 in Patients With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) of Dasatinib (BMS-354825) in patients in Japan.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dasatinib | tablets, Oral, 100 mg, once daily for 4 weeks |
| DRUG | Dasatinib | tablets, Oral, 150 mg, once daily, 4 weeks |
| DRUG | Dasatinib | tablets, Oral, 200 mg, once daily for 4 weeks |
Timeline
- Start date
- 2007-01-01
- Primary completion
- 2008-09-01
- Completion
- 2008-09-01
- First posted
- 2006-06-20
- Last updated
- 2010-12-15
- Results posted
- 2010-12-15
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00339144. Inclusion in this directory is not an endorsement.